Does Ozempic make you more fertile? This question has gained attention as more people use semaglutide for type 2 diabetes management. Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes in adults. Whilst there is no direct pharmacological link between Ozempic and enhanced fertility, the substantial weight loss often achieved during treatment may indirectly improve reproductive function in individuals with obesity-related fertility issues. Understanding this distinction is crucial, particularly as Ozempic is contraindicated during pregnancy and must be discontinued well before conception. This article examines the evidence, safety considerations, and essential guidance for anyone taking Ozempic who may be affected by fertility changes.

Understanding Ozempic and Its Primary Use

Ozempic (semaglutide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus in adults. It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a naturally occurring hormone that regulates blood sugar levels.

The medication functions through several mechanisms: it stimulates insulin secretion when blood glucose levels are elevated, suppresses the release of glucagon (a hormone that raises blood sugar), slows gastric emptying to reduce post-meal glucose spikes, and acts on appetite centres in the brain to promote satiety. Ozempic is administered as a once-weekly subcutaneous injection and is typically prescribed alongside diet and exercise modifications to improve glycaemic control.

Whilst Ozempic is not licensed as a weight-loss medication in the UK, significant weight reduction is a well-documented effect of treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide specifically for weight management under the brand name Wegovy, which contains a higher dose than Ozempic. Due to ongoing supply constraints, off-label prescribing of Ozempic for weight management is not currently recommended in the UK.

Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during the initial weeks of treatment. When used with insulin or sulfonylureas, Ozempic may increase the risk of hypoglycaemia (low blood sugar), and dose adjustments of these medications may be needed.

More serious but rare complications can include pancreatitis (seek urgent medical attention for severe, persistent abdominal pain with or without vomiting), gallbladder disease (symptoms include upper abdominal pain, fever, jaundice), and diabetic retinopathy complications. Severe, persistent vomiting or diarrhoea can lead to dehydration requiring medical attention.

Ozempic should not be used during pregnancy or breastfeeding. If you experience any suspected side effects, report them through the MHRA Yellow Card Scheme (website or app).

The Link Between Ozempic, Weight Loss and Fertility

The question of whether Ozempic directly increases fertility is complex and requires careful consideration of the evidence. There is no official link established between Ozempic and enhanced fertility as a direct pharmacological effect of the medication itself. However, the substantial weight loss that often accompanies Ozempic treatment may indirectly influence reproductive function in certain individuals.

Obesity is a well-recognised factor that can impair fertility in both women and men. In women, excess body weight is associated with ovulatory dysfunction, polycystic ovary syndrome (PCOS), irregular menstrual cycles, and reduced conception rates. The hormonal imbalances caused by obesity—including insulin resistance, elevated androgens, and disrupted leptin signalling—can significantly affect the hypothalamic-pituitary-ovarian axis. When individuals with obesity achieve clinically significant weight loss (typically 5–10% of body weight), improvements in ovulatory function and menstrual regularity are frequently observed, particularly in women with PCOS. The evidence for improved fertility with weight loss in men is more limited but suggests potential benefits for sperm parameters.

Therefore, if Ozempic facilitates substantial weight reduction in someone with obesity-related fertility issues, the metabolic improvements and hormonal rebalancing that accompany weight loss may restore more regular ovulation and potentially improve fertility. This is an indirect effect mediated through weight loss rather than a direct action of semaglutide on reproductive tissues.

It is important to note that anecdotal reports of unexpected pregnancies amongst Ozempic users have emerged, particularly in women who previously experienced difficulty conceiving. Whilst these accounts are noteworthy, they do not constitute clinical evidence of a direct fertility-enhancing effect.

Healthcare professionals should counsel patients that weight loss—regardless of the method—may alter fertility status, and appropriate contraception should be reviewed and optimised as weight loss progresses if pregnancy is not desired.

Why Ozempic Must Be Stopped Before Pregnancy

Ozempic is contraindicated during pregnancy and must be discontinued well in advance of conception. The primary concern relates to potential teratogenic effects and the lack of adequate safety data in pregnant women. Animal reproduction studies have demonstrated adverse developmental outcomes, including structural abnormalities and increased embryo-foetal mortality, when GLP-1 receptor agonists were administered during organogenesis.

The critical period of foetal organ development occurs during the first trimester, often before a woman realises she is pregnant. Given that Ozempic has a long half-life of approximately one week, the medication can remain in the system for several weeks after the last injection. The MHRA and the European Medicines Agency (EMA) recommend discontinuing Ozempic at least two months before a planned pregnancy to ensure adequate clearance of the drug from the body and minimise any potential risk to the developing foetus.

Additionally, the management of diabetes during pregnancy requires a different therapeutic approach. Insulin is the preferred treatment for glycaemic control in pregnancy, as it does not cross the placental barrier and has decades of safety data. Metformin may be continued or initiated as an adjunct or alternative in some cases, in line with NICE guidance. Women with type 2 diabetes who are planning pregnancy should be transitioned to appropriate therapy under specialist supervision, ideally before conception occurs.

Unplanned pregnancy whilst taking Ozempic requires prompt medical attention. If a patient discovers she is pregnant whilst using semaglutide, she should contact her GP or diabetes specialist immediately to discontinue the medication and arrange appropriate antenatal care. The healthcare team will assess glycaemic control, initiate insulin therapy if required, and arrange early pregnancy monitoring. Patients should be reassured that early discontinuation and appropriate management significantly reduce potential risks.

Ozempic should also not be used during breastfeeding, as it is unknown whether semaglutide is excreted in human milk and what effect it might have on the breastfed infant.

Contraception Requirements When Taking Ozempic

Given the potential fertility changes associated with weight loss and the contraindication of Ozempic in pregnancy, reliable contraception is essential for anyone of childbearing potential who does not wish to conceive whilst taking this medication. Healthcare professionals should have explicit discussions about contraceptive needs when initiating Ozempic therapy.

It's important to note that Ozempic does not reduce the effectiveness of oral contraceptives. According to the MHRA and the Faculty of Sexual and Reproductive Healthcare (FSRH), semaglutide has no clinically relevant effect on combined or progestogen-only oral contraceptives, and no routine additional contraceptive measures are required when starting Ozempic or increasing the dose.

However, the gastrointestinal side effects of Ozempic may potentially affect contraceptive efficacy in specific circumstances. If you experience vomiting within 2 hours of taking an oral contraceptive pill, or severe diarrhoea lasting more than 24 hours, follow the FSRH 'missed pill' guidance: use additional barrier contraception during the illness and for 7 days after recovery.

Recommended contraceptive options for individuals taking Ozempic include:

• Long-acting reversible contraception (LARC): intrauterine devices (copper or hormonal), contraceptive implants, and injectable progestogens are highly effective and unaffected by gastrointestinal symptoms

• Barrier methods: condoms (male or female) provide reliable protection when used correctly and consistently

• Non-oral hormonal methods: contraceptive patches and vaginal rings may be suitable alternatives, though patients should discuss these with their healthcare provider

• Oral contraceptives: combined or progestogen-only pills remain effective options with Ozempic, but follow missed pill guidance if vomiting or severe diarrhoea occurs

Regular review of contraceptive adequacy should form part of ongoing diabetes care consultations, particularly as weight loss progresses, which may increase fertility.

What to Do If You're Planning Pregnancy

If you are taking Ozempic and considering pregnancy, advance planning is crucial to optimise both maternal and foetal health outcomes. The first step is to arrange a preconception consultation with your GP or diabetes specialist, ideally several months before you intend to conceive. This allows sufficient time to adjust your diabetes management and ensure optimal glycaemic control before pregnancy.

Your healthcare team will advise you to discontinue Ozempic at least two months before attempting conception. During this period, alternative diabetes management strategies will be implemented. For most individuals, this involves transitioning to insulin therapy, which may include basal insulin, mealtime insulin, or a combination regimen tailored to your specific needs. Metformin may be continued or initiated if appropriate, in line with NICE guidance. Your diabetes team will provide comprehensive education on insulin administration, blood glucose monitoring, and hypoglycaemia management.

Optimising glycaemic control before conception is essential, as elevated blood glucose levels during early pregnancy significantly increase the risk of congenital abnormalities, miscarriage, and pregnancy complications. NICE guidelines recommend achieving an HbA1c level below 48 mmol/mol (6.5%) before discontinuing contraception, provided this can be accomplished without problematic hypoglycaemia. You should strongly avoid pregnancy if your HbA1c is above 86 mmol/mol (10%) and focus on improving control first. More frequent blood glucose monitoring—typically four to seven times daily—is usually necessary during the preconception period, and continuous glucose monitoring may be considered.

Additional preconception measures include:

• Folic acid supplementation: 5 mg daily (higher dose than standard) should be commenced at least three months before conception and continued through the first 12 weeks of pregnancy to reduce neural tube defect risk

• Medication review: assessment of all medications for pregnancy safety, including blood pressure medications, cholesterol-lowering drugs, and other diabetes medications

• Retinopathy screening: diabetic eye screening should be current, as pregnancy can accelerate retinopathy progression

• Renal function assessment: baseline kidney function tests to identify any pre-existing diabetic nephropathy

If you discover you are pregnant whilst taking Ozempic, contact your healthcare provider immediately—do not wait for a scheduled appointment. Prompt discontinuation and transition to appropriate pregnancy-safe diabetes management will be arranged as a matter of priority.

Frequently Asked Questions